Investments
3Portfolio Exits
1Funds
1Partners & Customers
10About Pierre Fabre
Pierre Fabre is a French pharmaceutical group. Founded and its headquarters still based in the South-west of France, Pierre Fabre has branches in countries and distribution agreements in over 130 countries. Covering all aspects of healthcare, from prescription drugs and OTC products to dermo-cosmetics, Pierre Fabre Laboratories employ over 10,000 people worldwide.
Pierre Fabre Headquarter Location
Avenue Hoche
Paris, 75008,
France
+33 (0)5 63.62.38.50
Latest Pierre Fabre News
Oct 12, 2021
IN BRIEF: McDermott Will & Emery, advised on the matter. McDermott Will & Emery advised Pierre Fabre S.A. with a team including Anne-France Moreau (Commercial Law), […]
Pierre Fabre Investments
3 Investments
Pierre Fabre has made 3 investments. Their latest investment was in Aglaia Therapeutics as part of their Seed VC on September 9, 2021.
Pierre Fabre Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/27/2021 | Seed VC | Aglaia Therapeutics | $4.7M | Yes | 2 | |
4/8/2021 | Series A | |||||
1/10/2018 | Corporate Minority |
Date | 9/27/2021 | 4/8/2021 | 1/10/2018 |
|---|---|---|---|
Round | Seed VC | Series A | Corporate Minority |
Company | Aglaia Therapeutics | ||
Amount | $4.7M | ||
New? | Yes | ||
Co-Investors | |||
Sources | 2 |
Pierre Fabre Portfolio Exits
1 Portfolio Exit
Pierre Fabre has 1 portfolio exit. Their latest portfolio exit was Pierre Fabre - Elancyl on November 06, 2020.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
11/6/2020 | Divestiture | 1 |
Date | 11/6/2020 |
|---|---|
Exit | Divestiture |
Companies | |
Valuation | |
Acquirer | |
Sources | 1 |
Pierre Fabre Acquisitions
2 Acquisitions
Pierre Fabre acquired 2 companies. Their latest acquisition was Igenica Biotherapeutics on May 24, 2017.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
5/24/2017 | Series F | $85.73M | Asset Sale | 1 | ||
1/15/2007 |
Date | 5/24/2017 | 1/15/2007 |
|---|---|---|
Investment Stage | Series F | |
Companies | ||
Valuation | ||
Total Funding | $85.73M | |
Note | Asset Sale | |
Sources | 1 |
Pierre Fabre Fund History
1 Fund History
Pierre Fabre has 1 fund, including Pierre Fabre Fund for Innovation.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
2/3/2016 | Pierre Fabre Fund for Innovation | 1 |
Closing Date | 2/3/2016 |
|---|---|
Fund | Pierre Fabre Fund for Innovation |
Fund Type | |
Status | |
Amount | |
Sources | 1 |
Pierre Fabre Partners & Customers
10 Partners and customers
Pierre Fabre has 10 strategic partners and customers. Pierre Fabre recently partnered with Y-Biologics on July 7, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
7/7/2021 | Licensor | Y-Biologics | South Korea | Y-Biologics, Pierre Fabre Enter Immuno-oncology Alliance Young Woo Park , CEO of Y-Biologics , said , `` We are very pleased to sign our first license agreement with Pierre Fabre . | 2 |
7/7/2021 | Vendor | Atos | France | Operational excellence : Through the transformation program implemented by Atos , Pierre Fabre 's Digital Acceleration & Information System department will become a true partner to the business teams , focusing on their needs and productivity . | 2 |
4/8/2021 | Licensee | Valenza Biotech | United States | ValenzaBio has entered into a license and commercialization agreement with Pierre Fabre for a monoclonal antibody directed to insulin-like growth factor 1 receptor , which ValenzaBio plans to progress into the clinic in the first half of 2022 . | 3 |
2/25/2021 | Licensor | ||||
11/23/2020 | Partner |
Date | 7/7/2021 | 7/7/2021 | 4/8/2021 | 2/25/2021 | 11/23/2020 |
|---|---|---|---|---|---|
Type | Licensor | Vendor | Licensee | Licensor | Partner |
Business Partner | Y-Biologics | Atos | Valenza Biotech | ||
Country | South Korea | France | United States | ||
News Snippet | Y-Biologics, Pierre Fabre Enter Immuno-oncology Alliance Young Woo Park , CEO of Y-Biologics , said , `` We are very pleased to sign our first license agreement with Pierre Fabre . | Operational excellence : Through the transformation program implemented by Atos , Pierre Fabre 's Digital Acceleration & Information System department will become a true partner to the business teams , focusing on their needs and productivity . | ValenzaBio has entered into a license and commercialization agreement with Pierre Fabre for a monoclonal antibody directed to insulin-like growth factor 1 receptor , which ValenzaBio plans to progress into the clinic in the first half of 2022 . | ||
Sources | 2 | 2 | 3 |
Pierre Fabre Team
9 Team Members
Pierre Fabre has 9 team members, including former Chief Executive Officer, Olivier Bohuon.
Name | Work History | Title | Status |
|---|---|---|---|
Olivier Bohuon | Chief Executive Officer | Former | |
Frederic Duchesne | Chief Executive Officer | Former | |
Christophe Durand | President, Chief Operating Officer | Former | |
Emmanuel SCHMIDT | Star Service, Groupe SEB, and Mazars | Chief Financial Officer | Former |
Francois Viargues | Chief Financial Officer | Former |
Name | Olivier Bohuon | Frederic Duchesne | Christophe Durand | Emmanuel SCHMIDT | Francois Viargues |
|---|---|---|---|---|---|
Work History | Star Service, Groupe SEB, and Mazars | ||||
Title | Chief Executive Officer | Chief Executive Officer | President, Chief Operating Officer | Chief Financial Officer | Chief Financial Officer |
Status | Former | Former | Former | Former | Former |